The Chemiverse Network module, employing various AI technologies and big data for drug design, has confirmed the effectiveness of a new CHK2 inhibitor in clinical trials for ovarian and breast cancer cells [142]. The gene discussed is CHEK2; the disease is breast carcinoma.